Azacitidine

🧮 Dose calculator

Myelodysplastic syndrome (MDS) · Regimen source: FDA Vidaza · 2.2FDA Vidaza · 2.3

• • Only under an oncologist in an equipped centre. Calculator = label mg/m² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal/hepatic function rest with the oncology team. FDA Vidaza · 2.2
• • May increase to 100 mg/m² after 2 cycles without benefit or toxicity (other than nausea). At least 4–6 cycles. Not interchangeable with oral azacitidine. FDA Vidaza · 2.3FDA Vidaza · 2.1

Enter age and weight.

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Vidaza · 8.1

  “Risk Summary Based on its mechanism of action and findings in animals, VIDAZA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )].”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Vidaza · 8.2

  “… s [see Nonclinical Toxicology ( 13.1 )] and the potential for serious adverse reactions in nursing infants from VIDAZA, advise patients not to breastfeed during treatment with VIDAZA and for 1 week after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Vidaza · 8.4

  “The safety and effectiveness of VIDAZA have been established in pediatric patients with newly diagnosed JMML aged 1 month and older and the information on this use is discussed throughout the labeling.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Vidaza · 8.5

  “Monitor renal function in these patients [see Dosage and Administration ( 2.7 ) and Warnings and Precautions ( 5.4 )].”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Vidaza · 8.3

  “Contraception Females Advise pregnant women of the potential risk to a fetus.”